Casma Therapeutics

Casma Therapeutics is a privately held biotechnology company founded in 2018 and headquartered in Boston, Massachusetts. The company is developing a new class of medicines based on the autophagy pathway — the cell's natural quality-control system for removing damaged components. Rather than pursuing conventional small-molecule or biologic inhibition, Casma aims to harness and enhance autophagic degradation to eliminate disease-causing elements inside cells. The centerpiece of the company's approach is its PHLYT™ (Phagosome-Lysosome Targeting) platform. According to Casma, PHLYT™ initiates target-specific autophagic degradation of disease targets independent of their size or complexity, allowing the company to address targets that current drugs have failed to reach. Casma describes itself as "a new kind of degradation company," differentiated by its focus on the autophagy pathway and its ability to identify autophagy disease targets beyond singular proteins. Casma's mission is to deliver novel therapeutics through a deeper understanding and engineering of autophagy, with the vision of restoring health by eliminating cellular damage. The company's team is composed of experts in molecular biology and drug discovery, and it emphasizes a collaborative culture — referring to its employees as "Casmaniacs." In November 2022, Casma Therapeutics announced it had raised $46.0 million in Series C funding, and the company presented at the Stifel 2022 Healthcare Conference. The company remains active in the biotechnology sector, pursuing partnerships and collaborations around its autophagy platform.

Casma Therapeutics was founded in 2018 and is headquartered in Boston, Massachusetts. The company was established around a scientific premise: that the autophagy pathway — the cellular process responsible for capturing and degrading damaged components — could be engineered into a therapeutic modality for diseases that existing drugs cannot address. From its inception, Casma positioned itself not as a conventional protein-degradation company but as "a new kind of degradation company focused on the autophagy pathway." Its founding team brought expertise in molecular biology and drug discovery, and the company built a discovery engine designed to identify autophagy disease targets beyond singular proteins. The company's core technological asset is its PHLYT™ (Phagosome-Lysosome Targeting) platform. According to Casma, PHLYT™ initiates target-specific autophagic degradation of disease targets independent of size or complexity. This platform underpins the company's pipeline and partnership strategy. By 2022, Casma had reached a significant financing milestone, announcing on November 15, 2022 that it had raised $46.0 million in Series C funding. Earlier that month, on November 8, 2022, the company announced it would present at the Stifel 2022 Healthcare Conference. These events marked Casma's continued activity and visibility in the biotechnology investment community. The company continues to operate as a private biotechnology company, promoting a collaborative culture — its employees are known internally as "Casmaniacs" — and pursuing its mission to deliver novel therapeutics through a deeper understanding and engineering of autophagy.

• 2022

  Announced presentation at Stifel 2022 Healthcare Conference.

• 2022

  Raised $46.0 million in Series C funding.

• 2018

  Casma Therapeutics founded and headquartered in Boston, MA.

A new kind of degradation company focused on reprogramming autophagy to eliminate diseases that current drugs have failed to target.

• PHLYT™ platform

  Phagosome-Lysosome Targeting platform that initiates target-specific autophagic degradation of disease targets independent of size or complexity.

1. 1Casma Therapeutics - Reprogramming autophagy to treat diseasecasmatx.com
2. 2About us - Casma Therapeuticscasmatx.com
3. 3Casma Therapeutics (United States) - Wikidatawikidata.org